【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: mAbs: Overview
• Evolution of mAb therapeutics
• Types of mAbs
• Conjugated cancer therapies using mAbs
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs
PART 08: Market segmentation by application
• Global oncology mAbs market
• Global autoimmune and inflammatory mAbs market
• TNF inhibitors
• IL-1 blockers
• PDE4 inhibitors
• Global respiratory mAbs market
• Global ophthalmology mAbs market
PART 09: Geographical segmentation
• Global mAbs market by geographical segmentation 2015-2020
• mAbs market in Americas
• mAbs market in US
• mAbs market in EMEA
• mAbs market in APAC
PART 10: Key leading countries
PART 11: Pipeline portfolio
PART 12: Market drivers
• Reimbursement benefits for mAbs and its biosimilars
• Special regulatory drug designations
• Increase in demand for ADCs
• Increase in industry-academia collaborations
PART 13: Impact of drivers
PART 14: Market challenges0
• Absence of adequate diagnosis and screening procedures
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Emergence of biosimilars
• Growing focus of vendors on untapped markets
• Focus on novel mechanisms
• Joint ventures and partnerships for R&D
• Emergence of targeted and combination therapies
PART 17: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Amgen
• Merck
• BMS
• Other prominent vendors
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for mAbs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Patent expiries of top selling mAbs by 2020 in US
Exhibit 09: Patent expiries of top selling mAbs by 2020 in Europe
Exhibit 10: Global mAbs market snapshot: Developed and emerging markets 2015
Exhibit 11: Global mAbs market 2015-2020 ($ billions)
Exhibit 12: Few patient assistance programs offered by various companies
Exhibit 13: Few awareness programs for various cancers, respiratory, and ophthalmology diseases
Exhibit 14: Impact of drivers and challenges on global mAbs market
Exhibit 15: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 16: Opportunities in mAbs industry today
Exhibit 17: Five forces analysis
Exhibit 18: Approved naked mAbs by US FDA and EU
Exhibit 19: Global mAbs market: Segmentation by application (2015-2020)
Exhibit 20: Global mAbs market: Segmentation by application 2015
Exhibit 21: Global mAbs market segmentation: Growth cycle analysis
Exhibit 22: Annual treatment cost per patient for various oncology drugs 2014
Exhibit 23: Global oncology mAbs market 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis of global oncology mAbs market by type of application
Exhibit 25: Market segmentation by MOA
Exhibit 26: Population aged 60 years and over (millions)
Exhibit 27: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 28: Global autoimmune and inflammatory mAbs market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global autoimmune and inflammatory mAbs market by application
Exhibit 30: Global autoimmune and inflammatory mAbs market segmentation by MOA
Exhibit 31: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 32: Global autoimmune and inflammatory mAbs market share by MOA 2015
Exhibit 33: Global respiratory mAbs market 2015-2020 ($ billions)
Exhibit 34: Opportunity analysis of global respiratory mAbs market by application
Exhibit 35: Global mAbs market segmentation by application 2015
Exhibit 36: Global ophthalmology mAbs market 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of global ophthalmology mAbs market by application
Exhibit 38: Global mAbs market: Geography outlook (2015-2020)
Exhibit 39: Global mAbs market: Geography outlook 2015
Exhibit 40: Revenue/growth outlook in different countries/regions 2015
Exhibit 41: mAbs market in Americas 2015-2020 ($ billions)
Exhibit 42: mAbs market in Americas by country 2015
Exhibit 43: mAbs market in US 2015-2020 ($ billions)
Exhibit 44: mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 45: mAbs market in EMEA by country 2015
Exhibit 46: Number of individuals treated with Herceptin through patient assistance programs in China
Exhibit 47: mAbs market in APAC 2015-2020 ($ billions)
Exhibit 48: mAbs market in APAC by country 2015
Exhibit 49: Global mAbs market by geographical segmentation 2015
Exhibit 50: Global mAbs market by geographical segmentation 2020
Exhibit 51: Global mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 52: Key leading countries
Exhibit 53: Pipeline share of global mAbs market 2015
Exhibit 54: Phase III pipeline molecules for mAbs
Exhibit 55: Phase II pipeline molecules for mAbs
Exhibit 56: Phase I pipeline molecules for mAbs
Exhibit 57: Special regulatory designations approved by US FDA
Exhibit 58: Special regulatory designations approved by EU
Exhibit 59: Impact of drivers
Exhibit 60: Impact of drivers and challenges
Exhibit 61: Expected combination regimen launches in oncology
Exhibit 62: Global mAbs market: Impact assessment of top trends 2015
Exhibit 63: Market presence of vendors in various therapy areas 2015
Exhibit 64: Market share analysis 2015
Exhibit 65: YoY sales comparison of top ten mAbs 2013-2015 ($ billions)
Exhibit 66: Competitive assessment of vendors
Exhibit 67: Key vendors: Geographical presence 2015
Exhibit 68: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 69: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 70: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 72: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 73: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Lucentis 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Xolair 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 79: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla 2015
Exhibit 80: Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 81: Actemra/RoActemra geographic segmentation by revenue 2015
Exhibit 82: F Hoffmann-La Roche: Metrics analysis
Exhibit 83: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 84: AbbVie: YoY revenue and growth rate of Humira (US) 2013-2015 ($ billions)
Exhibit 85: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
Exhibit 86: AbbVie: YoY revenue and growth rate of Synagis 2013-2015 ($ millions)
Exhibit 87: AbbVie: Metrics analysis
Exhibit 88: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
Exhibit 89: Johnson & Johnson: YoY growth rate and revenue of Remicade (US) 2013-2015 ($ billions)
Exhibit 90: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
Exhibit 91: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 92: Johnson & Johnson: YoY growth rate and revenue of Stelara (US) 2013-2015 ($ millions)
Exhibit 93: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
Exhibit 94: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ millions)
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (US) 2013-2015 ($ millions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2013-2015 ($ millions)
Exhibit 97: Johnson & Johnson: Metrics analysis
Exhibit 98: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 99: Amgen: Geographic segmentation of Xgeva 2015
Exhibit 100: Amgen: YoY growth and revenue generated from net product sales of Prolia 2013-2015 ($ billions)
Exhibit 101: Amgen: Geographical segmentation of Prolia 2015
Exhibit 102: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2013-2015 ($ millions)
Exhibit 103: Amgen: Geographical segmentation of Vectibix 2015
Exhibit 104: Amgen: Metrics analysis
Exhibit 105: Merck: YoY revenue and growth rate of Remicade (Europe, Russia, and Turkey) 2013-2015 ($ billions)
Exhibit 106: Merck: YoY revenue and growth rate of Simponi (Europe, Russia, and Turkey) 2013-2015 ($ millions)
Exhibit 107: Merck: Metrics analysis
Exhibit 108: BMS: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ billions)
Exhibit 109: BMS: Geographical segmentation of Yervoy 2015
Exhibit 110: BMS: YoY Revenue and growth rate of Erbitux in US and Canada 2013-2015 ($ millions)
Exhibit 111: BMS: Geographical segmentation of Yervoy 2015
Exhibit 112: BMS: Geographical segmentation of Opdivo 2015
Exhibit 113: BMS: Metrics analysis
【レポート販売概要】
■ タイトル：モノクローナル抗体（mAbs）の世界市場2016-2020■ 英文：Global Monoclonal Antibodies Market 2016-2020
■ 発行日：2016年7月20日
■ 調査会社：Technavio
■ 商品コード：IRTNTR9857
■ 調査対象地域：グローバル
- Permian Basin Royalty Trust：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an esse …
- ビールの世界市場2015-2019About Beer Beer is the highest consumed alcohol beverage in the world. It is also an integral part of the heritage and traditional cuisines in many countries, especially in Europe and the Americas. The growth of the global beer market is directly proportional to the global economic conditions. Technavio's analysts forecast the global beer market to grow at a CAGR of 2.97% in terms of revenue and 1 …
- 世界の主要な3Dプリンティング企業分析In a broad sense 3D printing is not a new phenomenon. The first commercial 3D printers were designed and launched in the United States in the late 1980s and early 1990s. However, additive manufacturing (AM) has now reached a growth phase after twenty years of incubation. With the number of vendor companies multiplying and new technologies being developed annually, the 3D printing market is undergo …
- 世界の保護コーティング剤市場（～2019）The report covers the protective coatings market on the basis of resin type, technology, applications, and geography. The market data for these types is given with respect to volume (Kilotons) and value ($million). The market size in terms of value of protective coatings was estimated to be $10,594.6 million in 2013, and is projected to grow with a CAGR of 9.75% from 2014 to 2019. The data mention …
- 世界の香水（香料）市場：ニュース、イベント動向（2014年3月）Synopsis The report provides a review of the latest news and key events in the global fragrances market during March 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global fragrances market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global …
- 世界の造影剤/コントラスト剤市場Contrast agents have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential …
- 世界のモバイル健康/フィットネス機器用センサー市場About Mobile Health and Fitness Sensors A sensor measures physical quantity and converts raw data into observable data, which are used by various industries. Mobile health and fitness sensors are used in health and fitness devices to measure various body parameters. Rapid and continuous development in sensing technology can assist in regular patient monitoring. This would help in bringing down hea …
- UC 2.0（ユニファイド・コミュニケーション2.0）サービスの世界市場About UC 2.0 services Enterprises focus on integrating their real-time communication tools such as text messaging, video conferencing, voice messaging, and other mobility features in their products to leverage the advancements in communication technology. The widespread implementation of unified communication has made business communication fast and has improved the business productivity. Usage of …
- 核酸ラベリングの世界市場：核酸ラベル試薬、核酸ラベルキット、サービスThe global nucleic acid labeling market is expected to USD 1,925.7 Million by 2020 from USD 1271.8 Million in 2015, at a CAGR of 8.65% between 2015 and 2020. The major drivers for the market include the increasing healthcare expenditure impacting personalized health technologies, increase in genomics research, rise in disease diagnosis, and increase in R&D spending are driving the growth of the gl …
- 保険業界向けテレマティクスの世界市場分析・予測（～2020）The insurance telematics market size is expected to grow from USD 857.2 Million in 2015 to USD 2.21 Billion in 2020, at a Compound Annual Growth Rate (CAGR) of 20.9%. The telematics market for industries such as insurance is anticipated to grow steadily in the next few years, due to decreasing cost of connectivity solutions, such as wireless and cellular modules and use of predictive analysis, ena …
- 圧縮ロードセルの世界市場展望2017-20276According to Stratistics MRC, the Global Compression Load Cells Market is accounted for $132.75 million in 2017 and is expected to reach $230.05 million by 2026 growing at a CAGR of 6.3% during the forecast period. Some of the key factors boosting the market are raising investment in industrial automation technologies and increasing usage of compression load cells in automotive assembly lines. How …
- 世界の自動車塗装市場動向（2012-2016）TechNavio's analysts forecast the Global Automotive Coatings market to grow at a CAGR of 5.89 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in automotive production and sales. The Global Automotive Coatings market has also been witnessing the increasing demand for high-performance coating. However, increasing government regulations and …
- アメリカの乳清タンパク質市場About whey protein Milk consists of two proteins that are casein protein and whey protein. Whey protein is separated from the casein protein in milk. It is also formed as a by-product of cheese making. It is regarded as a complete protein supplement as it is composed of all nine essential amino acids. Whey protein improves the dietary nutrient content and also has a positive effect on the immune s …
- アジアの手術室用装置市場見通し（～2021）Asia-Pacific Operating Room Equipment Market Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Operating Room Equipment Market Outlook to 2021", provides key market data on the Asia-Pacific Operating Room Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Operating Room Tables, Oper …
- 湿疹治療薬の世界市場：疾患別、地域別Global Eczema Therapeutics Market: About this market Technavio’s eczema therapeutics market analysis considers sales from atopic dermatitis, contact dermatitis, and other indication. Our study also finds the sales of eczema therapeutics in Asia, Europe, North America, and ROW. In 2019, the atopic dermatitis segment had a significant market share, and this trend is expected to continue over the for …
